🚨 Kicking off #ECCO2025 with a great ClinCom session led by @J_Kirchgesner

Fantastic talks and amazing people 🙏🏽

🚀 Are you passionate about shaping the future of gastroenterology? Join UEG’s Young Talent Group!

Learn more and apply by March 13: https://bit.ly/3p0zyJo
#myUEGcommunity #weareUEG

🎉The latest IBD-Ell newsletter is out!
- New trials added 🌟We've far surpassed 400 summarized trials🌟
- New guidelines
- New cheat sheet with lymphocyte trafficking and anti-integrins
Thanks for following along! www.ibd-eii.com
Subscribe for free anytime 📩
#IBD

It seems like things are picking up towards the end of the year 🏁🏎️

The VIVID-1 trial,mirikizumab in mod-severe #CD

Unlike SEQUENCE this is a double-blind, double-dummy, placebo-controlled AND active-control with ustekinumab AND not all patients had failed TNF

www.sciencedirect.com/science/arti...

The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach.

ow.ly/t2Ru50UahEi

Ok #GastroSky #IBDSky

Let’s discuss this paper!

Does VDZ become the drug of choice over anti-TNFs for prevention of post of CD recurrence?

Should history of previous biologic failure for active CD affect you choice of post-op prophylaxis?

REPOST to share to the IBD community, patient input pls!

Vedolizumab to prevent postoperative recurrence of Crohn's disease (the REPREVIO RCT)

"Vedolizumab prevented postoperative recurrence of CD & should be considered as a prophylactic treatment in individuals with risk factors for recurrence."

www.thelancet.com/journals/lan...

#GastroSky #IBDSky

go.bsky.app/CuwqDNF

I know I'm a bit late, but here's the updated table of #IBD treatments with their doses & routes of administration with the addition of guselkumalb

Full quality table ➡️ www.ibd-eii.com/ibdcheatsheet/

Induction with subcutaneous guselkumab in mod-severe Crohn's disease

- first phase 3 RCT with SC biologic induction
- includes bio-IR (anti-TNF and VDZ experienced) patients
- treat-trough with SC guselkumab
- effective and safe up to week 48

#IBDSky
@amcollegegastro.bsky.social

Upadacitinib in acute severe ulcerative colitis

- n=25 experience
- potentially useful therapy in ASUC
- still fairly high rates of colectomy (24%)

#IBDSKy
@amcollegegastro.bsky.social
@ibddoctor.bsky.social

Trying this out . Here mainly to learn and interact with IBD colleagues

This is the most important resource for people interested in inflammatory bowel disease

ibd-eii.com

It is run by Beatriz Gros

She is not on BlueSky yet. Please peer pressure her